Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the enestfreedom trial

HIGHLIGHTS

• who: Jerald P. Radich from the Charité-Universitätsmedizin Berlin, Berlin, Germany have published the research: Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial, in the Journal: (JOURNAL)
• what: The authors report here updated results based on a data cut-off date of 3rd February 2020, at which time all patients who entered the TFR phase had completed 5 years of TFR, switched to the re-initiation phase, or discontinued from the study. Nearly half of all patients who re-initiated nilotinib . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.